ATE538114T1 - 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten - Google Patents
4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheitenInfo
- Publication number
- ATE538114T1 ATE538114T1 AT09769671T AT09769671T ATE538114T1 AT E538114 T1 ATE538114 T1 AT E538114T1 AT 09769671 T AT09769671 T AT 09769671T AT 09769671 T AT09769671 T AT 09769671T AT E538114 T1 ATE538114 T1 AT E538114T1
- Authority
- AT
- Austria
- Prior art keywords
- 5utriazine
- pyridine
- derivatives
- treatment
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290617A EP2138488A1 (de) | 2008-06-26 | 2008-06-26 | 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen |
PCT/IB2009/006463 WO2009156860A2 (en) | 2008-06-26 | 2009-06-25 | Substituted triazinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE538114T1 true ATE538114T1 (de) | 2012-01-15 |
Family
ID=39832570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT09769671T ATE538114T1 (de) | 2008-06-26 | 2009-06-25 | 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten |
Country Status (23)
Country | Link |
---|---|
US (1) | US8592580B2 (de) |
EP (2) | EP2138488A1 (de) |
JP (1) | JP5581318B2 (de) |
KR (1) | KR20110025219A (de) |
CN (1) | CN102137854A (de) |
AR (1) | AR072227A1 (de) |
AT (1) | ATE538114T1 (de) |
AU (1) | AU2009263846A1 (de) |
BR (1) | BRPI0914662A2 (de) |
CA (1) | CA2729115A1 (de) |
CY (1) | CY1112642T1 (de) |
DK (1) | DK2321295T3 (de) |
EA (1) | EA201170095A1 (de) |
ES (1) | ES2379220T3 (de) |
IL (1) | IL210174A0 (de) |
MX (1) | MX2010014235A (de) |
NZ (1) | NZ590116A (de) |
PL (1) | PL2321295T3 (de) |
PT (1) | PT2321295E (de) |
SI (1) | SI2321295T1 (de) |
TW (1) | TW201004935A (de) |
WO (1) | WO2009156860A2 (de) |
ZA (1) | ZA201100026B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138493A1 (de) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Pyrimidon-Derivate |
EP2138498A1 (de) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituierte trizyklische Derivate gegen neurodegenerative Erkrankungen |
EP2138494A1 (de) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Alkylpyrimidin-4-one-Derivate |
EP2138485A1 (de) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituierte N-Oxid-Pyrazin-Derivate |
EP2138492A1 (de) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Pyrimidin-4-one-Derivate |
EP2138495A1 (de) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
JP6304492B2 (ja) * | 2012-03-30 | 2018-04-04 | 日産化学工業株式会社 | トリアジノン化合物及びt型カルシウムチャネル阻害剤 |
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
EP3985003B1 (de) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk-inhibitoren |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
WO2015189830A1 (en) | 2014-06-13 | 2015-12-17 | Fondazione Istituto Italiano Di Tecnologia | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease |
US20170057943A1 (en) * | 2015-08-17 | 2017-03-02 | Japan Tobacco Inc. | Hydroxytriazine compounds and pharmaceutical use thereof |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
CN115087643B (zh) * | 2021-01-15 | 2023-10-27 | 中国医药研究开发中心有限公司 | 稠和杂环类化合物及其制备方法和医药用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5170780A (ja) * | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinabenzoguanidoruino seiho |
EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
HU178496B (en) | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
US4406897A (en) | 1981-07-06 | 1983-09-27 | William H. Rorer, Inc. | 6-Aryl-4-hydrazinyl-s-triazin-2-ones |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
CA2234641A1 (en) | 1995-11-01 | 1997-05-09 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
EP1136484A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Arylalkylamino)pyrimidonderivate |
CA2445697A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2003027115A1 (en) | 2001-09-21 | 2003-04-03 | Sanofi-Synthelabo | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
JP4646626B2 (ja) | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド3−キナーゼβの阻害 |
EP1454909B1 (de) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one und 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one Derivate und deren Benutzung gegen neurodegenerative Krankheiten |
EP1460076A1 (de) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituierte 8-Perfluoro-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-on-Derivate |
ES2330789T3 (es) * | 2005-06-30 | 2009-12-15 | Janssen Pharmaceutica Nv | Anilino-piridinotriazinas ciclicas como inhibidores de gsk-3. |
EP1790649A1 (de) | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituierte bicyclische Pyrimidone Derivaten |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
US20110039893A1 (en) * | 2006-10-11 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Gsk-3beta inhibitor |
EP1992624A1 (de) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamid-Pyrimidon-Verbindungen |
EP2138495A1 (de) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate |
EP2138485A1 (de) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituierte N-Oxid-Pyrazin-Derivate |
EP2138492A1 (de) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Pyrimidin-4-one-Derivate |
EP2138494A1 (de) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Alkylpyrimidin-4-one-Derivate |
EP2138493A1 (de) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituierte Pyrimidon-Derivate |
-
2008
- 2008-06-26 EP EP08290617A patent/EP2138488A1/de not_active Withdrawn
-
2009
- 2009-06-24 AR ARP090102315A patent/AR072227A1/es unknown
- 2009-06-24 TW TW098121235A patent/TW201004935A/zh unknown
- 2009-06-25 PL PL09769671T patent/PL2321295T3/pl unknown
- 2009-06-25 KR KR1020117001908A patent/KR20110025219A/ko not_active Application Discontinuation
- 2009-06-25 JP JP2011515667A patent/JP5581318B2/ja not_active Expired - Fee Related
- 2009-06-25 WO PCT/IB2009/006463 patent/WO2009156860A2/en active Application Filing
- 2009-06-25 EP EP09769671A patent/EP2321295B1/de active Active
- 2009-06-25 ES ES09769671T patent/ES2379220T3/es active Active
- 2009-06-25 SI SI200930201T patent/SI2321295T1/sl unknown
- 2009-06-25 EA EA201170095A patent/EA201170095A1/ru unknown
- 2009-06-25 DK DK09769671.0T patent/DK2321295T3/da active
- 2009-06-25 MX MX2010014235A patent/MX2010014235A/es not_active Application Discontinuation
- 2009-06-25 PT PT09769671T patent/PT2321295E/pt unknown
- 2009-06-25 AU AU2009263846A patent/AU2009263846A1/en not_active Abandoned
- 2009-06-25 CA CA2729115A patent/CA2729115A1/en not_active Abandoned
- 2009-06-25 CN CN2009801334844A patent/CN102137854A/zh active Pending
- 2009-06-25 AT AT09769671T patent/ATE538114T1/de active
- 2009-06-25 NZ NZ590116A patent/NZ590116A/en not_active IP Right Cessation
- 2009-06-25 BR BRPI0914662A patent/BRPI0914662A2/pt not_active IP Right Cessation
-
2010
- 2010-12-15 US US12/968,935 patent/US8592580B2/en not_active Expired - Fee Related
- 2010-12-22 IL IL210174A patent/IL210174A0/en unknown
-
2011
- 2011-01-03 ZA ZA2011/00026A patent/ZA201100026B/en unknown
-
2012
- 2012-03-16 CY CY20121100288T patent/CY1112642T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2321295T1 (sl) | 2012-04-30 |
MX2010014235A (es) | 2011-06-24 |
CA2729115A1 (en) | 2009-12-30 |
JP2011525905A (ja) | 2011-09-29 |
BRPI0914662A2 (pt) | 2015-10-20 |
AR072227A1 (es) | 2010-08-11 |
EP2138488A1 (de) | 2009-12-30 |
TW201004935A (en) | 2010-02-01 |
DK2321295T3 (da) | 2012-04-10 |
EP2321295A2 (de) | 2011-05-18 |
EA201170095A1 (ru) | 2011-08-30 |
NZ590116A (en) | 2011-10-28 |
KR20110025219A (ko) | 2011-03-09 |
PL2321295T3 (pl) | 2012-06-29 |
PT2321295E (pt) | 2012-03-23 |
AU2009263846A1 (en) | 2009-12-30 |
CN102137854A (zh) | 2011-07-27 |
US8592580B2 (en) | 2013-11-26 |
ZA201100026B (en) | 2012-04-25 |
IL210174A0 (en) | 2011-03-31 |
CY1112642T1 (el) | 2016-02-10 |
JP5581318B2 (ja) | 2014-08-27 |
US20110144114A1 (en) | 2011-06-16 |
EP2321295B1 (de) | 2011-12-21 |
WO2009156860A3 (en) | 2010-03-04 |
WO2009156860A2 (en) | 2009-12-30 |
ES2379220T3 (es) | 2012-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE538114T1 (de) | 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
DK2300443T3 (da) | Triazolderivater, der er anvendelige til behandling af sygdomme | |
SMT201600080B (it) | Inibitori di chinasi janus per il trattamento di occhio secco e altre malattie oculari | |
ATE523508T1 (de) | Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate | |
DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
NZ627586A (en) | Pyridone derivatives | |
DK2432798T3 (da) | 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme | |
HRP20130357T1 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases. | |
ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
BRPI0912855A2 (pt) | derivados de indazóis substituídos por fenila ou piridinila | |
UA111725C2 (uk) | Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол | |
DK3135672T3 (da) | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme | |
IT1391866B1 (it) | Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari. | |
BRPI0906618A2 (pt) | Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta | |
ATE534633T1 (de) | Indazolderivate zur behandlung von hsp90- induzierten krankheiten | |
DK2041093T3 (da) | Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer | |
DK2987791T3 (da) | 3-(4-(Benzyloxy)phenyl)hex-4-insyre-derivat, egnet til forebyggelse og behandling af metaboliske sygdomme | |
ATE502944T1 (de) | 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs | |
DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
BRPI0915130A2 (pt) | derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c | |
DK2987798T3 (da) | Trehalosederivater og farmaceutiske sammensætninger til behandling af neurodegenerative sygdomme, der indeholder disse | |
DE602008005930D1 (de) | 3-(2,2,2-trimethylhydrazinium) propionat-salze zur behandlung des myokardinfarktes |